ImClone gets $6.1 billion offer from unknown bidder

NEW YORK A mystery company has offered to buy ImClone for $6.1 billion, ImClone said.

ImClone wouldn’t name the company, but its $70-per-share offer was more than the $60-per-share one that Bristol-Myers Squibb offered.

Bristol-Myers Squibb owns 17 percent of ImClone. The two companies profit from the drug Erbitux, a cancer treatment that had 2007 sales of $1.3 billion.